

PRESS RELEASE

Shareholders of Geneba approve all agenda items during AGM

Amsterdam, 17 May 2016 – At today’s Annual General Meeting of Shareholders (“AGM”) of Geneba Properties N.V. (“Geneba”) all agenda items have been approved.

The AGM adopted the financial statements for the financial year 2015. Over 2015 Geneba reported positive Direct investment result (FFO) of € 25.9 million. Updated property and derivatives valuations have led to a net result of € 30.2 million (2014: € 7.1 million negative). In view of Geneba’s growth strategy, the AGM approved the resolution not to pay out dividend.

Other resolutions that have been adopted are:

- Discharge of the Management Board and the Supervisory Board
- Designation of the Management Board as the body authorised to issue shares and to grant rights to subscribe for shares and to limit or exclude pre-emptive rights upon the issue of shares or granting of rights to subscribe for shares
- PricewaterhouseCoopers Accountants N.V. have been appointment as external auditor

For more information, please go to www.geneba.com

###

About Geneba

Geneba Properties N.V. (“Geneba”) is a European commercial real estate company that commenced business in 2014 and is headquartered in Amsterdam, the Netherlands. The company now owns and manages a property portfolio of over € 730 million consisting mainly of long-term leased corporate real estate assets in Germany and the Netherlands.

Geneba’s investment strategy focuses on corporate real estate assets which serve its tenants as operational basis, providing “a home to their businesses”. The main investments targets are logistics and light industrial buildings in Germany and the Netherlands. Geneba’s shares trade at NPEX. Geneba is subject to the supervision of the Dutch financial regulator, AFM. For more information: www.geneba.com.

For more information please contact:

Citigate First Financial

Ingrid Prins Ingrid.Prins@citigateff.nl / +31 (0)20 575 4078 / +31 (0)6 515 92484

Jan van Ewijk Jan.VanEwijk@citigateff.nl / +31 (0)20 575 4011 / +31 (0)6 153 39471